Hoth Therapeutics Faces Delisting Concerns

Ticker: HOTH · Form: 8-K · Filed: 2024-11-01T00:00:00.000Z

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

Related Tickers: HOTH

TL;DR

HOTH might be delisted, trading could be affected.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on November 1, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates a potential transfer of listing, with the earliest event reported as October 30, 2024. The company is incorporated in Nevada and its principal executive offices are located in New York, NY.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact the company's stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe indicator of financial instability or regulatory non-compliance.

Key Players & Entities

FAQ

What specific listing rule or standard has Hoth Therapeutics, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that Hoth Therapeutics, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the earliest event date reported in this 8-K filing?

The earliest event date reported in this 8-K filing is October 30, 2024.

What is the filing date of this 8-K report?

This 8-K report was filed on November 1, 2024.

In which state is Hoth Therapeutics, Inc. incorporated?

Hoth Therapeutics, Inc. is incorporated in Nevada.

Where are Hoth Therapeutics, Inc.'s principal executive offices located?

Hoth Therapeutics, Inc.'s principal executive offices are located at 590 Madison Ave., 21st Floor, New York, New York 10022.

From the Filing

0001213900-24-093514.txt : 20241101 0001213900-24-093514.hdr.sgml : 20241101 20241101161536 ACCESSION NUMBER: 0001213900-24-093514 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20241101 DATE AS OF CHANGE: 20241101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241419281 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 ea0219197-8k_hoththera.htm CURRENT REPORT false 0001711786 0001711786 2024-10-30 2024-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) October 30, 2024   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   590 Madison Ave. , 21 st Floor New York , New York 10022 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.   On October 30, 2024, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq C

View on Read The Filing